The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Launched by ALNYLAM PHARMACEUTICALS · Jul 27, 2015
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
- • Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent
- Exclusion Criteria:
- • Any new or uncontrolled condition that could make the participant unsuitable for participation
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneering biopharmaceutical company focused on the development of innovative therapies based on RNA interference (RNAi) technology. Founded in 2002, Alnylam is dedicated to transforming the treatment landscape for patients with genetically defined diseases by leveraging its proprietary platform to discover and develop novel therapeutics. With a robust pipeline of clinical programs targeting a range of conditions, including rare genetic disorders and prevalent diseases, Alnylam is committed to advancing scientific research and improving patient outcomes through cutting-edge medicine and rigorous clinical trials. The company emphasizes collaboration and transparency in its operations, fostering partnerships within the scientific community to drive innovation and enhance healthcare solutions globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sofia, , Bulgaria
Chicago, Illinois, United States
Vancouver, British Columbia, Canada
Boston, Massachusetts, United States
Rio De Janeiro, , Brazil
Le Kremlin Bicetre, , France
Marseille Cedex, , France
Lisbon, , Portugal
Porto, , Portugal
Barcelona, , Spain
Palma De Mallorca, , Spain
Umeå, , Sweden
La Mesa, California, United States
Baltimore, Maryland, United States
Detroit, Michigan, United States
Rochester, Minnesota, United States
Saint Louis, Missouri, United States
New York, New York, United States
Buenos Aires, , Argentina
Westmead, , Australia
Nicosia, , Cyprus
Creteil, , France
Heidelberg, , Germany
Muenster, , Germany
Pavia, , Italy
Rome, , Italy
Sicily, , Italy
Kumamoto, , Japan
Kuala Lumpur, , Malaysia
Groningen, , Netherlands
Huelva, , Spain
Madrid, , Spain
Istanbul, , Turkey
Seoul, , Korea, Republic Of
London, , United Kingdom
Aurora, Colorado, United States
Jacksonville, Florida, United States
Joplin, Missouri, United States
Cooperstown, New York, United States
Columbus, Ohio, United States
São Paulo, , Brazil
Fort De France, Martinique, France
Saint Pierre, Reunion Island, France
Lille, , France
Cologne, , Germany
Ehime, , Japan
Fukuoka, , Japan
Hiroshima, , Japan
Nagano, , Japan
Okawasuji, , Japan
Ono, , Japan
ōita, , Japan
Tlalpan, , Mexico
Taipei, , Taiwan
Patients applied
Trial Officials
Medical Director
Study Director
Alnylam Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials